Latest Healthcare News

Page 72 of 150
Amplia Therapeutics has successfully raised A$2.65 million through its Share Purchase Plan, exceeding expectations and bolstering funding for pivotal clinical trials of its lead drug narmafotinib.
Ada Torres
Ada Torres
26 Aug 2025
Austco Healthcare has reported a robust FY25 with revenues climbing 40% to $81.4 million and EBITDA jumping 62% to $13 million, driven by organic growth and strategic acquisitions.
Ada Torres
Ada Torres
26 Aug 2025
Nanosonics delivered a robust FY25 with 17% revenue growth and a 72% jump in profit before tax, propelled by next-gen trophon devices and advancing CORIS commercialisation.
Ada Torres
Ada Torres
26 Aug 2025
Australian Clinical Labs delivered solid FY25 financial results with revenue up 6.4% and EBIT rising 8.7%, underpinned by operational efficiencies and strategic innovation. The company’s FY26 guidance signals continued growth amid evolving market conditions and government fee pressures.
Ada Torres
Ada Torres
26 Aug 2025
Australian Clinical Labs reported robust FY25 financial results with revenue and earnings growth, alongside a strong dividend payout and positive outlook for FY26.
Ada Torres
Ada Torres
26 Aug 2025
Australian Clinical Labs reported a 6.4% revenue increase and an 8.7% rise in underlying EBIT for FY25, maintaining disciplined growth and operational efficiency in a complex healthcare environment.
Ada Torres
Ada Torres
26 Aug 2025
Holista Colltech has inked a binding supply and development agreement with US-based Regenerex Pharma to exclusively supply proprietary ovine collagen for advanced wound care products, targeting the lucrative US market initially with plans for global expansion.
Ada Torres
Ada Torres
26 Aug 2025
Firebrick Pharma has closed a $1.4 million placement to fund expansion of its Nasodine nasal spray in key international markets and advance new product development.
Ada Torres
Ada Torres
26 Aug 2025
Imricor Medical Systems reports significant regulatory approvals and clinical trial progress, positioning itself as a disruptive force in the growing electrophysiology market. With a strengthened commercial pipeline and solid cash reserves, the company is poised for a pivotal growth phase.
Ada Torres
Ada Torres
26 Aug 2025
Imricor Medical Systems reported a sharp 52% revenue decline and a 92% increase in net loss for H1 2025, offset by a $42.8 million equity raise boosting liquidity. The company is investing heavily in European sales and clinical trials while pursuing FDA approval.
Ada Torres
Ada Torres
26 Aug 2025
Actinogen Medical reports steady progress in its Alzheimer’s and depression drug trials, backed by strong funding and strategic commercial planning. Key interim data from the pivotal XanaMIA trial is expected early next year.
Ada Torres
Ada Torres
25 Aug 2025
Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.
Ada Torres
Ada Torres
25 Aug 2025